Schrag Anette, Taddei Raquel N
UCL Institute of Neurology, London, United Kingdom.
King's College Hospital, London, United Kingdom.
Int Rev Neurobiol. 2017;133:623-655. doi: 10.1016/bs.irn.2017.05.024. Epub 2017 Jul 21.
Depression and anxiety are some of the most common comorbidities arising in patients with Parkinson's disease. However, their timely recognition and diagnosis are often hindered by overlap with other somatic features and a low rate of self-report. There is a need for greater awareness and for better assessment and treatment options are highly required. Currently available scales can serve as tools to monitor change over time and the effect of interventional strategies. Development of new therapeutic strategies, including nonpharmacological approaches such as transcranial magnetic stimulation and deep brain stimulation, may provide alternatives to currently available treatment approaches. In this chapter we will give an overview of the most recent advances in the diagnosis and treatment of these important nonmotor symptoms.
抑郁和焦虑是帕金森病患者中最常见的一些共病。然而，它们的及时识别和诊断常常因与其他躯体特征重叠以及自我报告率低而受到阻碍。需要提高认识，并且迫切需要更好的评估和治疗选择。目前可用的量表可作为监测随时间变化以及干预策略效果的工具。新治疗策略的开发，包括经颅磁刺激和深部脑刺激等非药物方法，可能为目前可用的治疗方法提供替代方案。在本章中，我们将概述这些重要非运动症状诊断和治疗的最新进展。
